Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.

The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...

From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

Once a booming field, bustling with innovation and money driving that innovation, the cell and gene therapy sector is now struggling to fuel therapeutic growth to bring medicines to patients. It doesn ...

Nature writes the best horror stories – In The New York Times’ recent piece, the return of the screwworm, a flesh‑eating parasite once eradicated from the U.S. Indeed, cattle ranchers are once again ...

The news that the organization led a $35 million funding round for London-based Portal Biotech came about two weeks ago. Portal Biotech’s focus is on the field of proteomics, which is the study of ...

When Turnstone Biologics was founded, its team had high hopes for the California-based biotech to “lead the fight against solid tumors.” At first, it was keen on developing oncolytic viruses, which ...

Antibody therapies constitute a vast global market: currently valued at over $250 billion, the market for antibodies is expected to exceed $850 billion worldwide by 2032. Driving forces behind this ...

We’re nearly halfway through 2025, and like clockwork, the American Society of Clinical Oncology (ASCO) annual summit took place from the 30th of May to the 3rd of June in Chicago this year. With ...

In the heat of the COVID-19 crisis, a wave of vaccine companies stepped into the spotlight with unprecedented speed and visibility. Riding a surge of public and private funding, they raced to develop ...

Dive into this whitepaper and learn about: The limitations of current hybridoma and single B cell screening techniques Why traditional discovery workflows are inefficient and prone to overlooking ...